Nuvalent (NUVL) Assets Average (2021 - 2026)
Nuvalent's (NUVL) quarterly Assets Average came in at $1.4 billion in Q1 2026, up 22.08% YoY from $1.1 billion in Q1 2025, and up 14.68% on a QoQ basis from $1.2 billion in Q4 2025.
Nuvalent (NUVL) Assets Average (2021 - 2026) Analysis & Trends
Nuvalent (NUVL) has 6 years of Assets Average data on file, last reported at $1.4 billion in Q1 2026.
- Quarterly Assets Average rose 22.08% year-over-year to $1.4 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.4 billion (up 22.08% YoY) and the FY2025 annual result came in at $1.3 billion, up 36.3% from the prior year.
- Assets Average improved to $1.4 billion in Q1 2026, from $1.2 billion in the prior quarter.
- In the past five years, Assets Average ranged from a high of $1.4 billion in Q1 2026 to a low of $256.3 million in Q3 2022.
- A 5-year average of $729.3 million and a median of $691.8 million in 2024 frame the typical range for Assets Average.
- Annual changes were most pronounced in 2024 — Assets Average surged 115.0% — and 2025, when it rose 2.66%.
- Tracing NUVL's Assets Average over 5 years: stood at $366.0 million in 2022, then surged by 58.12% to $578.7 million in 2023, then soared by 101.35% to $1.2 billion in 2024, then grew by 2.66% to $1.2 billion in 2025, then advanced by 14.68% to $1.4 billion in 2026.
- The last three Assets Average figures came in at $1.4 billion (Q1 2026), $1.2 billion (Q4 2025), and $1.0 billion (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 3.29 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.86 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 16.08 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.34 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.09 Bn |
| 10 | Nuvalent | 9.10 Bn | 9.10 Bn | - | 1.37 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.37 Bn |
| Dec 31, 2025 | 1.20 Bn |
| Sep 30, 2025 | 1.01 Bn |
| Jun 30, 2025 | 1.07 Bn |
| Mar 31, 2025 | 1.12 Bn |
| Dec 31, 2024 | 1.17 Bn |
| Sep 30, 2024 | 932.04 Mn |
| Jun 30, 2024 | 691.85 Mn |
| Mar 31, 2024 | 720.43 Mn |
| Dec 31, 2023 | 578.73 Mn |
| Sep 30, 2023 | 433.51 Mn |
| Jun 30, 2023 | 451.47 Mn |
| Mar 31, 2023 | 471.72 Mn |
| Dec 31, 2022 | 366.01 Mn |
| Sep 30, 2022 | 256.29 Mn |
| Jun 30, 2022 | 270.03 Mn |
| Mar 31, 2022 | 285.43 Mn |
| Dec 31, 2021 | 300.90 Mn |
| Sep 30, 2021 | 225.74 Mn |